Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FUCA1 | P04066 | 2/20 | 0.57 |
| ▸ | DRD2 | P14416 | 4/20 | 0.56 |
| ▸ | DRD3 | P35462 | 4/20 | 0.56 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.47 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.46 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
| ▸ | GBA1 | P04062 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18517577 | 0.90 | FUCA1 (0.65) | FUCA1DRD2DRD3GRIN2BS1PR1 | |
| SCHEMBL742892 | 0.90 | FUCA1 (0.65) | FUCA1DRD2DRD3GRIN2BS1PR1 | |
| Hydrochloric Acid SCHEMBL11771300 | 0.88 | FUCA1 (0.62) | FUCA1DRD2DRD3GRIN2BS1PR1 | |
| SCHEMBL22784542 | 0.85 | FUCA1 (0.69) | FUCA1DRD2DRD3GRIN2BS1PR1 | |
| SCHEMBL22784440 | 0.85 | FUCA1 (0.69) | FUCA1DRD2DRD3GRIN2BS1PR1 | |
| SCHEMBL15996691 | 0.85 | FUCA1 (0.69) | FUCA1DRD2DRD3GRIN2BS1PR1 | |
| SCHEMBL758420 | 0.85 | FUCA1 (0.69) | FUCA1DRD2DRD3GRIN2BS1PR1 | |
| SCHEMBL288640 | 0.85 | FUCA1 (0.69) | FUCA1DRD2DRD3GRIN2BS1PR1 | |
| SCHEMBL21777260 | 0.84 | FUCA1 (0.53) | FUCA1DRD2DRD3GRIN2BSIGMAR1 | |
| SCHEMBL21777836 | 0.84 | FUCA1 (0.53) | FUCA1DRD2DRD3GRIN2BSIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12060351-B2 | Thiadiazole IRAK4 inhibitors | GILEAD SCIENCES, INC. (US) | 2024-08-13 | — | — | US | disclosed |
| CN-112566915-B | Thiadiazole IRAK4 inhibitors | 吉利德科学公司 | 2024-04-09 | — | — | CN | disclosed |
| US-11702414-B2 | Thiadiazole IRAK4 inhibitors | GILEAD SCIENCES, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| US-20220402910-A1 | THIADIAZOLE IRAK4 INHIBITORS | GILEAD SCIENCES, INC. | 2022-12-22 | — | — | US | disclosed |
| US-20220402910-A1 | THIADIAZOLE IRAK4 INHIBITORS | GILEAD SCIENCES, INC. | 2022-12-22 | — | — | US | disclosed |
| US-20220098187-A1 | THIADIAZOLE IRAK4 INHIBITORS | GILEAD SCIENCES, INC. | 2022-03-31 | — | — | US | disclosed |
| US-11046686-B2 | Thiadiazole IRAK4 compounds | GILEAD SCIENCES, INC. (US) | 2021-06-29 | — | — | US | disclosed |
| US-11046686-B2 | Thiadiazole IRAK4 compounds | GILEAD SCIENCES, INC. (US) | 2021-06-29 | — | — | US | disclosed |
| EP-3837261-A1 | THIADIAZOLE IRAK4 INHIBITORS | Gilead Sciences, Inc. (US) | 2021-06-23 | — | — | EP | disclosed |
| CN-112566915-A | Thiadiazole IRAK4 inhibitor | 吉利德科学公司 | 2021-03-26 | — | — | CN | disclosed |
| US-20200079769-A1 | THIADIAZOLE IRAK4 COMPOUNDS | GILEAD SCIENCES, INC. | 2020-03-12 | — | — | US | disclosed |
| WO-2020036986-A1 | THIADIAZOLE IRAK4 INHIBITORS | GILEAD SCIENCES, INC. (US) | 2020-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11046686-B2 | Thiadiazole IRAK4 compounds | IRAK4, IRAK3, IRAK2 | FUCA1 4525/4885DRD2 3478/4885DRD3 3497/4885 |
| US-20220098187-A1 | THIADIAZOLE IRAK4 INHIBITORS | IRAK4, IRAK3, IRAK1 | FUCA1 4428/4885DRD2 3676/4885DRD3 3666/4885 |
| US-12060351-B2 | Thiadiazole IRAK4 inhibitors | IRAK4, IRAK3, IRAK1 | FUCA1 4428/4885DRD2 3676/4885DRD3 3666/4885 |
| US-20200079769-A1 | THIADIAZOLE IRAK4 COMPOUNDS | IRAK4, IRAK3, IRAK2 | FUCA1 4525/4885DRD2 3478/4885DRD3 3497/4885 |
| US-11702414-B2 | Thiadiazole IRAK4 inhibitors | IRAK4, IRAK3, IRAK1 | FUCA1 4428/4885DRD2 3676/4885DRD3 3666/4885 |
| US-20220402910-A1 | THIADIAZOLE IRAK4 INHIBITORS | IRAK4, IRAK3, IRAK1 | FUCA1 4428/4885DRD2 3676/4885DRD3 3666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.